MiR-181a enhances drug sensitivity in mitoxantone-resistant breast cancer cells by targeting breast cancer resistance protein (BCRP/ABCG2)

Jiao, Xuyang; Zhao, Lin; Ma, Mengtao; Bai, Xuefeng; He, Miao; Yan, Yuanyuan; Wang, Yan; Chen, Qiuchen; Zhao, Xinnan; Zhou, Mingyi; Cui, Zeshi; Zheng, Zhaohui; Wang, Enhua; Wei, Minjie

doi:10.1007/s10549-013-2607-x

Cited by 92 publications

(54 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are several miRNA that have been identified in a wide range of cancer cells, as potential inhibitors of ABCG2 expression (such as miRNA-328, -hsa-miR-328, -519, -520h, -212, -181a, 487a and miR-302 [200][201][202][203][204][205] . The use of miRNA to interfere with transporter transcription confirmed the role of ABCG2 in drug resistance related signaling pathways.…”

Section: Abcg2 Inhibitorsmentioning

confidence: 99%

“…Use of microRNA has revealed a more complex role of ABCG2 in drug resistance related signaling pathways: SIRT1/CREB/ABCG2 and Wnt/β-catenin-ABCG2 pathway Breast, ovarian cancer, other cell lines [200][201][202][203][204][205][206][207] TKI: tyrosine kinase inhibitor; MDR: multidrug resistance; CML: chronic myeloid leukemia; NSCLC: non-small cell lung cancer their inhibition will also increase the oral bioavailability of the drug, in addition to its penetration to the tumor site. However, since these two transporters are also expressed in sanctuary sites, caution for potential toxic side effects should be considered.…”

Section: Dual Inhibitorsmentioning

confidence: 99%

See 1 more Smart Citation

How to overcome ATP-binding cassette drug efflux transporter-mediated drug resistance?

Jaramillo¹,

Saig²,

Cloos³

et al. 2018

CDR

View full text Add to dashboard Cite

P-glycoprotein (ABCB1), multidrug resistance protein-1 (ABCC1) and breast cancer resistance protein (ABCG2) belong to the ATP-binding cassette (ABC) superfamily of proteins that play an important physiological role in protection of the body from toxic xenobiotics and endogenous metabolites. Beyond this, these transporters determine the toxicity profile of many drugs, and confer multidrug resistance (MDR) in cancer cells associated with a poor treatment outcome of cancer patients.It has long been hypothesized that inhibition of ABC drug efflux transporters will increase drug accumulation and thereby overcome MDR, but until now no approved inhibitor of these transporters is available in the clinic. In this review we present molecular strategies to overcome this type of drug resistance and discuss for each of these strategies their promising value or indicate underlying reasons for their limited success.

show abstract

Section: Abcg2 Inhibitorsmentioning

confidence: 99%

Section: Dual Inhibitorsmentioning

confidence: 99%

How to overcome ATP-binding cassette drug efflux transporter-mediated drug resistance?

Jaramillo¹,

Saig²,

Cloos³

et al. 2018

CDR

View full text Add to dashboard Cite

show abstract

“…Liao Pan et al, 2009b;To et al, 2009;Wang et al, 2010;Li et al, 2011;Padmanabhan et al, 2012;Jiao et al, 2013;Ma et al, 2013 Kida et al, 2011;Tong et al, 2011;Zhou et al, 2011 NR1C3 Nuclear Receptor miR-130, -27b, -27a Jennewein et al, 2010 Kim et al, 2010;Lee et al, 2012 NR1C2 Nuclear Receptor miR-15a, -199a, -214, -9 Yin et al, 2010el Azzouzi et al, 2013;Thulin et al, 2013 NR1H3 …”

Section: Micrornas Regulate the Expression Of Adme Phase I And Ii Enzmentioning

confidence: 99%

“…Among the 105 miRNA candidates, 14 of them were Ramirez Borel et al, 2012;Kim et al, 2012;Goedeke et al, 2013;Kang et al, 2013;Rottiers et al, 2013;Zhang et al, 2014;Zhao et al, 2014 -298, -354, -7, -200c, -19a/b Kovalchuk et al, 2008;Zhu et al, 2008;Pogribny et al, 2010;Bitarte et al, 2011;Bao et al, 2012;J Chen et al, 2012b -124, -203, -26a, -135b, -145 Furuta et al, 2010;Borel et al, 2012ABCG1 Transporter miR-33 Marquart et al, 2010Rayner et al, 2010 ABCG2/BCRP Transporter miR-520h, -519c, -328, -487a, -181a Liao et al, 2008;Pan et al, 2009b;To et al, 2009;Wang et al, 2010;Li et al, 2011;Padmanabhan et al, 2012;Jiao et al, 2013;Ma et al, 2013SLC6A4 Transporter miR-16, -15a Baudry et al, 2010Tamarapu Parthasarathy et al, 2012;Moya et al, 2013 NR2B1/RXRA Nuclear Receptor miR-27a, -27b Ji et al, 2009;Komagata et al, 2009;Mohri et al, 2009 NR1I1/VD receptor Nuclear Receptor miR-27b, -125b Mohri et al, 2009;Pan et al, 2009aNR1C1 Nuclear Receptor miR-10b, -506, -21, -27b Zheng et al, 2010Kida et al, 2011;Tong et al, 2011;Zhou et al, 2011NR1C3 N...…”

Section: Micrornas Regulate the Expression Of Adme Phase I And Ii Enzmentioning

confidence: 99%

“…CYP3A4 can be induced by ligands that bind and activate the pregnane X (PX) receptor (Lehmann et al, 1998). Experimental data also indicate that the level of CYP3A4 is affected by epigenetic factors, including histone acetylation and methylation (Dannenberg and Edenberg, 2006;Kacevska et al, 2012) and also miRNAs.A recent study based upon several different miRNA target prediction programmes identified 105 miRNAs that may potentially interact with CYP3A4 mRNA -124, -203, -26a, -135b, -145 Furuta et al, 2010;Borel et al, 2012 ABCG1 Transporter miR-33 Marquart et al, 2010Rayner et al, 2010 ABCG2/BCRP Transporter miR-520h, -519c, -328, -487a, -181aLiao Pan et al, 2009b;To et al, 2009;Wang et al, 2010;Li et al, 2011;Padmanabhan et al, 2012;Jiao et al, 2013;Ma et al, 2013 Kida et al, 2011;Tong et al, 2011;Zhou et al, 2011 NR1C3 Nuclear Receptor miR-130, -27b, -27a Jennewein et al, 2010 Kim et al, 2010;Lee et al, 2012 NR1C2 Nuclear Receptor miR-15a, -199a, -214, -9 Yin et al, 2010el Azzouzi et al, 2013;Thulin et al, 2013 NR1H3 …”

mentioning

confidence: 99%

See 1 more Smart Citation

The effects of microRNA on the absorption, distribution, metabolism and excretion of drugs

Chevillet

Liu

et al. 2014

British J Pharmacology

View full text Add to dashboard Cite

The importance of genetic factors (e.g. sequence variation) in the absorption, distribution, metabolism, excretion (ADME) and overall efficacy of therapeutic agents is well established. Our ability to identify, interpret and utilize these factors is the subject of much clinical investigation and therapeutic development. However, drug ADME and efficacy are also heavily influenced by epigenetic factors such as DNA/histone methylation and non-coding RNAs [especially microRNAs (miRNAs)]. Results from studies using tools, such as in silico miRNA target prediction, in vitro functional assays, nucleic acid profiling/sequencing and high-throughput proteomics, are rapidly expanding our knowledge of these factors and their effects on drug metabolism. Although these studies reveal a complex regulation of drug ADME, an increased understanding of the molecular interplay between the genome, epigenome and transcriptome has the potential to provide practically useful strategies to facilitate drug development, optimize therapeutic efficacy, circumvent adverse effects, yield novel diagnostics and ultimately become an integral component of personalized medicine. LINKED ARTICLESThis article is part of a themed section on Epigenetics and Therapy. To view the other articles in this section visit http://dx.doi. org/10.1111/bph.2015.172.issue-11 Abbreviations ABC, ATP-binding cassette; ABCB1/MDR1/P-gp, multidrug resistance protein 1/P-glycoprotein; ADME, absorption, distribution, metabolism, excretion; antimiR, miRNA antagonist; CYP450, cytochrome P450; DOX, doxorubicin; ESR1, oestrogen receptor alpha; ETS1, V-Ets avian erythroblastosis virus E26 oncogene homologue 1; GPX7, glutathione peroxidase 7; GSS, glutathione synthetase; HDAC, histone deacetylase; LXRA, liver X receptor α; miRNA, microRNA; mRNA, messenger RNA; ncRNA, non-coding RNA; NR1C1, PPARα; PK, pharmacokinetic; PXR, pregnane X receptor; RISC, RNA-induced silencing complex; RXR, retinoid X receptor; SLC, solute carrier; UGT, UDP-glucuronosyltransferase; UTR, untranslated region; VD receptor, vitamin D receptor The proper control of absorption, distribution, metabolism and excretion (ADME) of xenobiotics is essential for living organisms to obtain energy, acquire necessary building blocks (e.g. essential amino acids) and maintain homeostasis in a complex chemical environment. Genes involved in ADME activities encode various receptor/transporters, biotransformation enzymes and accessory proteins (PharmaADME, http://pharmaadme.org/joomla/). These proteins include membrane transporters responsible for the absorption and excretion of specific molecules and enzymes to convert xenobiotics for excretion. To date, over 300 transporters and enzymes directly involved in ADME process have been described. This long list of components makes the study of ADME inherently complex, as transporters and enzymes work in concert to respond dynamically to diverse external factors. Despite the formidable complexity of the field, an understanding of ADME is critical for drug development in order...

show abstract

TGF‐β1 elevates P‐gp and BCRP in hepatocellular carcinoma through HOTAIR/miR‐145 axis

Kong

Qiu

et al. 2019

Biopharm & Drug Disp

View full text Add to dashboard Cite

Multidrug resistance (MDR) is common in patients and has been linked to transforming growth factor‐β1 (TGF‐β1) and overexpression of drug efflux transporters P‐glycoprotein (P‐gp) and breast cancer resistance protein (BCRP), although the molecular mechanisms remain largely unknown. This study aimed to investigate the mechanisms underlying TGF‐β1‐induced MDR in hepatocellular carcinoma (HCC) cells. It was found that TGF‐β1 upregulated HOX transcript antisense RNA (HOTAIR) expression in HCC cells. When drosophila mothers against decapentaplegic 4 (SMAD4) was silenced, HOTAIR expression was accordingly reduced. Meanwhile, miR‐145 expression was increased in the case HOTAIR was silenced. If the enhancer of zeste homolog 2 (EZH2) was knocked down using small interfering RNA (siRNA), miR‐145 expression was decreased. Then, the regulatory role of miR‐145 in P‐gp and BCRP expression was explored. The results showed that the expression of P‐gp and BCRP protein was suppressed by miR‐145 through binding to the 3′‐untranslated regions (3′‐UTRs) of P‐gp and BCRP. In conclusion, our study revealed a novel mechanism explaining TGF‐β1‐induced MDR in HCC through upregulating P‐gp and BCRP via the SMAD4/HOTAIR/miR‐145 axis.

show abstract

MiR-181a enhances drug sensitivity in mitoxantone-resistant breast cancer cells by targeting breast cancer resistance protein (BCRP/ABCG2)

Cited by 92 publications

References 45 publications

How to overcome ATP-binding cassette drug efflux transporter-mediated drug resistance?

How to overcome ATP-binding cassette drug efflux transporter-mediated drug resistance?

The effects of microRNA on the absorption, distribution, metabolism and excretion of drugs

TGF‐β1 elevates P‐gp and BCRP in hepatocellular carcinoma through HOTAIR/miR‐145 axis

Contact Info

Product

Resources

About